ARCHIVES

Virus Studies Approved By DCE Board for $2.5 Mil. In First Year

This article is from The Cancer Letter archive.

Vol. 15 No. 42 | November 3, 1989

Download PDF Visit The Full Archive

Related Articles

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

May 31, 2013

Taxol Approved By FDA For Ovarian Cancer; Bristol Sets Price Tier In Line With Platinum

January 8, 1993

Monoclonal Antibody Improves AML Response To Therapy

July 26, 2002

Study: Molecular Breast Imaging Can Be As Effective as MRI

July 27, 2012

DCT Board Okays Concepts For New Radiation Studies

June 12, 1987

HAS Authority Over Cancer Program Become Hot Issues; Fredrickson Opposes Exemption For NCI

October 29, 1976